Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT07508735
Active, not recruiting Not applicable

Bioavailability of Phlorotannins and Carotenoids Following the Intake of Crackers Fortified With Seaweed

NCT07508735 · tracked via the Priya Life Science Spain tracker
Sponsor
National Research Council, Spain
Phase
Not applicable
Started
2026-03-01
Last updated
2026-04-02

Condition(s) studied

Bioavailability Heathy VolunteersBioavailability and AUC

Investigational drug(s) / intervention(s)

Seaweed crackerControl cracker

Seaweed cracker: Four crackers (20 g) fortified with seaweed Himanthalia elongata

Control cracker: Four crackers (20 g) without seaweed in its composition

Study summary

The study aims to evaluate the bioavailability of phlorotannins and carotenoids from the seaweed Himanthalia elongata in healthy individuals after the consumption of a cracker fortified with this plant species. The study consists of an acute, blinded, randomized, controlled, crossover trial in which each participant consumes both the fortified cracker and a control cracker without seaweed. This design allows the comparison of the bioavailability of these compounds when incorporated into a bakery-based food matrix.

Eligibility

Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Body mass index: 18-30 Kg/m2 Exclusion Criteria: * Following a vegetarian diet * Being pregnant * Suffering from digestive diseases (such as irritable bowel syndrome, gastrointestinal ulcers, etc.) * Having a history of hypersensitivity or allergies to components of the study foods * Following any medication regimen * Currently taking or having recently taken antibiotics * Having donated blood within the three months prior to the study

Primary outcome measure(s)

  • Targeted metabolic analysis of phlorotannins in blood/urine samples — 2 moths
    Targeted metabolomic analysis of phlorotannins in plasma and urine samples will be conducted using HPLC-QTOF-MS. Quantification of the concentration (μM) will be carried out employing authentic commercial standards, ensuring accurate and reliable measurement of target compounds.

Trial sites (1)

FacilityCityRegionStatus
Institute of Food Science, Technology and Nutrition, Spanish National Research Council (ICTAN-CSIC) Madrid Madrid

More National Research Council, Spain trials in Spain

Cardiometabolic Properties of Omega-3 Functionalized With Hydroxytyrosol Active, not recruiting
New Insights Into the Biological Activity Evaluation of Mango Juices Processed by Sustainable Emerging Technologies Starting soon
Polyphenol Metabolism and Personalized Nutrition in Menopause (PolyPause). Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07508735 on ClinicalTrials.gov ↗ ← All trials in Spain